The SDNA-1000 offers single device integration for both DNA and viral RNA applications. Spectrum’s CV3 patented blue preservation chemistry is 100% bacteriostatic delivering 100% inactivation of the live virus providing the most robust and safest biomaterial collection approach for the detection and diagnosis of disease or infection.
Spectrum reduces sample self-collection errors with its intuitive product design for those offering direct-to-patient diagnostic testing or teams that may have experienced clinical study or project failures from sample self-collection errors of the past.
The SDNA saliva collection device additionally offers over 10 days of post-collection stability with no degradation of sample efficacy and ships with verified, unique barcode serialization for biosample physical and digital chain-of-custody. Additionally, customized packaging, kitting, and fulfillment options are available to solve any special project or testing workflow requirements.
For many, choosing the wrong saliva collection device has introduced, and often increased critical failure points. Spectrum’s new and technically-superior saliva collection device is the answer your teams and projects have been waiting for.
The first saliva collection device to be authorized for COVID-19 testing, the SDNA-1000 was shown to be a robust source of viral RNA and proven to deliver a safer and more accurate testing sample when compared to traditional swabbing.